{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:23:00Z","timestamp":1788362580460,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northern Ireland Kidney Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-transplant Immunoglobulin A Nephropathy (IgAN) is an important cause of premature graft loss. Management strategies are often extrapolated from native IgAN, with available evidence limited to heterogeneous, predominantly small retrospective studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterise diagnostic criteria, map management strategies, and summarise associated clinical outcomes in post-transplant IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was performed in MEDLINE, Embase, Web of Science, and Scopus (1st January 2000\u201311th December 2025) following Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines. English-language studies of adult kidney transplant recipients with biopsy-proven post-transplant IgAN and documented management strategies were included. Data on study design, cohorts, diagnostic criteria, interventions, and outcomes were charted and narratively described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven studies met the inclusion criteria. Most were single-centre retrospective cohorts. Diagnostic criteria varied, but typically histological evidence of IgA deposition alone was sufficient. IgAN was often clinically relevant, with proteinuria\u2009&gt;\u20091\u00a0g\/day frequently reported. Reported treatments included renin-angiotensin-aldosterone system (RAAS)-blockade, immunosuppression adjustment, rituximab, tonsillectomy and pulsed corticosteroids. Several small case series explored emerging therapies (iptacopan, budesonide, telitacicept). Study heterogeneity precluded quantitative data synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RAAS-blockade was the most commonly used intervention and was associated with benefit in several studies. Tonsillectomy was associated with improved outcomes but reported only in Japanese cohorts. Other interventions (rituximab, pulsed steroids, emerging therapies) warrant prospective clinical trials. Amid evolving paradigms in native IgAN management, this review highlights heterogeneity in diagnostic criteria, outcome reporting, and interventions for the management of post-transplant IgAN. Robust prospective, multicentre studies are urgently required to define optimal management in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05260-x","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T02:25:20Z","timestamp":1787192720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0955-3599","authenticated-orcid":false,"given":"Samuel","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"4","key":"5260_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transpl. 2018;33(4):661\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfx189.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"5260_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338. https:\/\/doi.org\/10.2215\/CJN.0000000000000135.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5260_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","volume":"10","author":"G Moroni","year":"2019","unstructured":"Moroni G, Belingheri M, Frontini G, Tamborini F, Messa P. Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation. Front Immunol. 2019;10:1332. https:\/\/doi.org\/10.3389\/fimmu.2019.01332.","journal-title":"Front Immunol"},{"issue":"2","key":"5260_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ndt\/gfy168","volume":"34","author":"H Burton","year":"2019","unstructured":"Burton H, Iyamu Perisanidou L, Steenkamp R, Evans R, Mumford L, Evans KM, et al. Causes of renal allograft failure in the UK: trends in UK Renal Registry and National Health Service Blood and Transplant data from 2000 to 2013. Nephrol Dial Transpl. 2019;34(2):355\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfy168.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"5260_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323. https:\/\/doi.org\/10.1038\/s41581-024-00885-3.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"5260_CR6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1097\/TP.0000000000001093","volume":"100","author":"ML Wyld","year":"2016","unstructured":"Wyld ML, Chadban SJ. Recurrent IgA Nephropathy After Kidney Transplantation. Transplantation. 2016;100(9):1827\u201332. https:\/\/doi.org\/10.1097\/TP.0000000000001093.","journal-title":"Transplantation"},{"key":"5260_CR7","doi-asserted-by":"publisher","first-page":"101878","DOI":"10.1016\/j.trim.2023.101878","volume":"80","author":"A Sani","year":"2023","unstructured":"Sani A, Movalled K, Kamanaj A, Hassannezhad S, Hosseinifard H, et al. Interventions for decreasing the risk of recurrent IgA nephropathy: A systematic review and meta-analysis. Transpl Immunol. 2023;80:101878. https:\/\/doi.org\/10.1016\/j.trim.2023.101878.","journal-title":"Transpl Immunol"},{"key":"5260_CR8","doi-asserted-by":"publisher","first-page":"141277017","DOI":"10.3389\/fimmu.2023.1277017","volume":"28","author":"Y Li","year":"2023","unstructured":"Li Y, Tang Y, Lin T, Song T. Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis. Front Immunol. 2023;28:141277017. https:\/\/doi.org\/10.3389\/fimmu.2023.1277017.","journal-title":"Front Immunol"},{"issue":"3","key":"5260_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/transplantology4030016","volume":"4","author":"HS Han","year":"2023","unstructured":"Han HS, Lubetzky ML, Anandasivam NS, Cox RA, Lee BK. Recurrent Immunoglobulin A Nephropathy after Kidney Transplant \u2013 An Updated Review. Transplantology. 2023;4(3):161\u201377. https:\/\/doi.org\/10.3390\/transplantology4030016.","journal-title":"Transplantology"},{"issue":"5","key":"5260_CR10","doi-asserted-by":"publisher","first-page":"151570","DOI":"10.1016\/j.semnephrol.2025.151570","volume":"44","author":"SC Ong","year":"2024","unstructured":"Ong SC, Julian BA. Post-transplant IgA Nephropathy. Semin Nephrol. 2024;44(5):151570. https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151570.","journal-title":"Semin Nephrol"},{"issue":"4","key":"5260_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.11124\/JBIES-21-00242","volume":"20","author":"MDJ Peters","year":"2022","unstructured":"Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953\u201368. https:\/\/doi.org\/10.11124\/JBIES-21-00242.","journal-title":"JBI Evid Synth"},{"issue":"1","key":"5260_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"5260_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"key":"5260_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"2","key":"5260_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1034\/j.1399-0012.2003.02067.x","volume":"17","author":"HJ Jeong","year":"2003","unstructured":"Jeong HJ, Kim YS, Kwon KW, Kim MS, Kim S, Choi KH, et al. Segmental glomerulosclerosis in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril. Clin Transpl. 2003;17(2):108\u201313. https:\/\/doi.org\/10.1034\/j.1399-0012.2003.02067.x.","journal-title":"Clin Transpl"},{"key":"5260_CR16","doi-asserted-by":"publisher","unstructured":"Namba Y, Oka K, Moriyama T, Ichimaru N, Kyo M, Kokado Y et al. Risk factors for graft loss in patients with recurrent IGA nephropathy after renal transplantation. Transplant Proc. 2004;36(5):1314\u20136. https:\/\/doi.org\/10.1016\/j.transproceed.2004.05.044.","DOI":"10.1016\/j.transproceed.2004.05.044"},{"issue":"11","key":"5260_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1440-1827.2004.01751.x","volume":"54","author":"HJ Jeong","year":"2004","unstructured":"Jeong HJ, Kim YS, Kwon KH, Kim SI, Kim MS, Choi KH, et al. Glomerular crescents are responsible for chronic graft dysfunction in post-transplant IgA nephropathy. Pathol Int. 2004;54(11):837\u201342. https:\/\/doi.org\/10.1111\/j.1440-1827.2004.01751.x.","journal-title":"Pathol Int"},{"issue":"6","key":"5260_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/ndt\/gfh773","volume":"20","author":"A Chandrakantan","year":"2005","unstructured":"Chandrakantan A, Ratanapanichkich P, Said M, Barker CV, Julian BA. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transpl. 2005;20(6):1214\u201321. https:\/\/doi.org\/10.1093\/ndt\/gfh773.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"5260_CR19","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1093\/ndt\/gfl506","volume":"21","author":"AE Courtney","year":"2006","unstructured":"Courtney AE, McNamee PT, Nelson WE, Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transpl. 2006;21(12):3550\u20134. https:\/\/doi.org\/10.1093\/ndt\/gfl506.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"5260_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1016\/j.transproceed.2007.08.025","volume":"39","author":"C Mousson","year":"2007","unstructured":"Mousson C, Charon-Barra C, De La Vega MF, Tanter Y, Justrabo E, Martin L, et al. Recurrence of IgA Nephropathy With Crescents in Kidney Transplants. Transpl Proc. 2007;39(8):2595\u20136. https:\/\/doi.org\/10.1016\/j.transproceed.2007.08.025.","journal-title":"Transpl Proc"},{"issue":"6","key":"5260_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/08860220802134516","volume":"30","author":"Z Tang","year":"2008","unstructured":"Tang Z, Ji SM, Chen DR, Wen JQ, Chen JS, Liu ZH, et al. Recurrent or De Novo IgA Nephropathy with Crescent Formation after Renal Transplantation. Ren Fail. 2008;30(6):611\u20136. https:\/\/doi.org\/10.1080\/08860220802134516.","journal-title":"Ren Fail"},{"issue":"7","key":"5260_CR22","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.transproceed.2008.07.008","volume":"40","author":"K Kiattisunthorn","year":"2008","unstructured":"Kiattisunthorn K, Premasathian N, Wongwiwatana A, Parichatikanond P, Cheunsuchon B, Vasuvattakul S. Evaluating the Clinical Course and Prognostic Factors of Posttransplantation Immunoglobulin A Nephropathy. Transpl Proc. 2008;40(7):2349\u201354. https:\/\/doi.org\/10.1016\/j.transproceed.2008.07.008.","journal-title":"Transpl Proc"},{"issue":"s20","key":"5260_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1399-0012.2009.01003.x","volume":"23","author":"H Ushigome","year":"2009","unstructured":"Ushigome H, Suzuki T, Fujiki M, Nobori S, Sakamoto S, Okamoto M, et al. Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transpl. 2009;23(s20):17\u201322. https:\/\/doi.org\/10.1111\/j.1399-0012.2009.01003.x.","journal-title":"Clin Transpl"},{"issue":"7","key":"5260_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/TP.0b013e3181b75374","volume":"88","author":"T Kennoki","year":"2009","unstructured":"Kennoki T, Ishida H, Yamaguchi Y, Tanabe K. Proteinuria-Reducing Effects of Tonsillectomy Alone in IgA Nephropathy Recurring After Kidney Transplantation. Transplantation. 2009;88(7):935\u201341. https:\/\/doi.org\/10.1097\/TP.0b013e3181b75374.","journal-title":"Transplantation"},{"issue":"s26","key":"5260_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/ctr.12194","volume":"27","author":"K Koshino","year":"2013","unstructured":"Koshino K, Ushigome H, Sakai K, Suzuki T, Nobori S, Okajima H, et al. Outcome of tonsillectomy for recurrent IgA nephropathy after kidney transplantation. Clin Transpl. 2013;27(s26):22\u20138. https:\/\/doi.org\/10.1111\/ctr.12194.","journal-title":"Clin Transpl"},{"issue":"12","key":"5260_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/nep.12151","volume":"18","author":"K Hotta","year":"2013","unstructured":"Hotta K, Fukasawa Y, Akimoto M, Tanabe T, Sasaki H, Fukuzawa N, et al. Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology. 2013;18(12):808\u201312. https:\/\/doi.org\/10.1111\/nep.12151.","journal-title":"Nephrology"},{"issue":"2","key":"5260_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.transproceed.2013.11.066","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang Y, Ichimaru N, Kyo M, Kakuta Y, Okumi M, Kaimori JY, et al. Beneficial Effects of Tonsillectomy for Mesangial Immunoglobulin A (IgA) Deposition and Clinical Outcome in Five Kidney Transplant Patients With Recurrent IgA Nephropathy: Case Report. Transpl Proc. 2014;46(2):607\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2013.11.066.","journal-title":"Transpl Proc"},{"issue":"4","key":"5260_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40620-016-0314-5","volume":"29","author":"M Messina","year":"2016","unstructured":"Messina M, Di Vico MC, Ariaudo C, Mazzucco G, Fop F, Segoloni GP, et al. Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. J Nephrol. 2016;29(4):575\u201383. https:\/\/doi.org\/10.1007\/s40620-016-0314-5.","journal-title":"J Nephrol"},{"issue":"1","key":"5260_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41100-016-0090-7","volume":"3","author":"H Nihei","year":"2017","unstructured":"Nihei H, Sakai K, Shishido S, Sibuya K, Edamatsu H, Aikawa A. Efficacy of tonsillectomy for the treatment of immunoglobulin A nephropathy recurrence after kidney transplantation. Ren Replace Ther. 2017;3(1):10. https:\/\/doi.org\/10.1186\/s41100-016-0090-7.","journal-title":"Ren Replace Ther"},{"key":"5260_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.12659\/AOT.907167","volume":"23","author":"DB Cordeiro Cabral","year":"2018","unstructured":"Cordeiro Cabral DB, De Sandes-Freitas TV, Medina-Pestana JO, Mastroianni-Kirsztajn G. Clinical Features, Treatment and Prognostic Factors of Post-Transplant Immunoglobulin A Nephropathy. Ann Transpl. 2018;23:166\u201375. https:\/\/doi.org\/10.12659\/AOT.907167.","journal-title":"Ann Transpl"},{"issue":"S2","key":"5260_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nep.13272","volume":"23","author":"Y Matsukuma","year":"2018","unstructured":"Matsukuma Y, Masutani K, Tsuchimoto A, Okabe Y, Nakamura M, Kitazono T, et al. Effect of steroid pulse therapy on post-transplant immunoglobulin A nephropathy. Nephrology. 2018;23(S2):10\u20136. https:\/\/doi.org\/10.1111\/nep.13272.","journal-title":"Nephrology"},{"issue":"17","key":"5260_CR32","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.3390\/jcm10173939","volume":"10","author":"W Chancharoenthana","year":"2021","unstructured":"Chancharoenthana W, Leelahavanichkul A, Ariyanon W, Vadcharavivad S, Phumratanaprapin W. Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study. J Clin Med. 2021;10(17):3939. https:\/\/doi.org\/10.3390\/jcm10173939.","journal-title":"J Clin Med"},{"key":"5260_CR33","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.3389\/ti.2022.10693","volume":"35","author":"M Lopez-Martinez","year":"2022","unstructured":"Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, et al. Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. Transpl Int. 2022;35:10693. https:\/\/doi.org\/10.3389\/ti.2022.10693.","journal-title":"Transpl Int"},{"issue":"5","key":"5260_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2023.02.012","volume":"103","author":"I Gandolfini","year":"2023","unstructured":"Gandolfini I, Alibrandi S, Gentile M, Russo LS, Fiaccadori E, Palmisano A, et al. Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation. Kidney Int. 2023;103(5):995\u20136. https:\/\/doi.org\/10.1016\/j.kint.2023.02.012.","journal-title":"Kidney Int"},{"issue":"12","key":"5260_CR35","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.ajt.2025.08.015","volume":"25","author":"E Sanna","year":"2025","unstructured":"Sanna E, Nicassio SR, Mella A, Mingozzi S, Manzione AM, Dolla C, et al. Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation. Am J Transpl. 2025;25(12):2651\u20137. https:\/\/doi.org\/10.1016\/j.ajt.2025.08.015.","journal-title":"Am J Transpl"},{"issue":"8","key":"5260_CR36","doi-asserted-by":"publisher","first-page":"sfaf232","DOI":"10.1093\/ckj\/sfaf232","volume":"18","author":"L Xu","year":"2025","unstructured":"Xu L, Wu S, Zhang P, Wang F, Di W, Zhong S, et al. Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation. Clin Kidney J. 2025;18(8):sfaf232. https:\/\/doi.org\/10.1093\/ckj\/sfaf232.","journal-title":"Clin Kidney J"},{"issue":"1","key":"5260_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nep.12722","volume":"22","author":"W Chancharoenthana","year":"2017","unstructured":"Chancharoenthana W, Townamchai N, Leelahavanichkul A, Wattanatorn S, Kanjanabuch T, Avihingsanon Y, et al. Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms. Nephrology. 2017;22(1):65\u201371. https:\/\/doi.org\/10.1111\/nep.12722.","journal-title":"Nephrology"},{"issue":"5","key":"5260_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/ndt\/15.5.689","volume":"15","author":"K Oka","year":"2000","unstructured":"Oka K, Imai E, Moriyama T, Akagi Y, Ando A, Hori M, et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transpl. 2000;15(5):689\u201395. https:\/\/doi.org\/10.1093\/ndt\/15.5.689.","journal-title":"Nephrol Dial Transpl"},{"key":"5260_CR39","doi-asserted-by":"publisher","unstructured":"Ganesh K, Jayaram JK, Thomas RM, Abraham TT, Kumar JS, Simon SS et al. Immunoglobulin a deposits in renal allografts: a prospective longitudinal single-center study. Transplant .Proc. 2024;56(1):97\u2013104. https:\/\/doi.org\/10.1016\/j.transproceed.2023.11.023","DOI":"10.1016\/j.transproceed.2023.11.023"},{"issue":"1","key":"5260_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12882-019-1537-1","volume":"20","author":"S Park","year":"2019","unstructured":"Park S, Baek CH, Go H, Kim YH, Min S, Ha J, et al. Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study. BMC Nephrol. 2019;20(1):354. https:\/\/doi.org\/10.1186\/s12882-019-1537-1.","journal-title":"BMC Nephrol"},{"issue":"8","key":"5260_CR41","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","volume":"16","author":"A Uffing","year":"2021","unstructured":"Uffing A, P\u00e9rez-Sa\u00e9z MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, et al. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clin J Am Soc Nephrol. 2021;16(8):1247\u201355. https:\/\/doi.org\/10.2215\/CJN.00910121.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"5260_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12882-018-1025-z","volume":"19","author":"A Uffing","year":"2018","unstructured":"Uffing A, P\u00e9rez-S\u00e1ez MJ, La Manna G, Comai G, Fischman C, Farouk S, et al. A large, international study on post-transplant glomerular diseases: the TANGO project. BMC Nephrol. 2018;19(1):229. https:\/\/doi.org\/10.1186\/s12882-018-1025-z.","journal-title":"BMC Nephrol"},{"issue":"10405","key":"5260_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4.","journal-title":"Lancet"},{"issue":"11","key":"5260_CR44","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/j.ekir.2023.08.007","volume":"8","author":"M Haas","year":"2023","unstructured":"Haas M. Variability in Diagnosis and Treatment of Recurrent IgA Nephropathy in Kidney Transplants: Results of Surveys of Renal Pathologists and Nephrologists. Kidney Int Rep. 2023;8(11):2486\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.007.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"5260_CR45","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313. https:\/\/doi.org\/10.1681\/ASN.2016060640.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5260_CR46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"5260_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024;390(1):20\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2305635.","journal-title":"N Engl J Med"},{"issue":"3","key":"5260_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","volume":"108","author":"L Kooienga","year":"2025","unstructured":"Kooienga L, Lo J, Lee EY, Kim SG, Thomas H, Workeneh B, et al. Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney Int. 2025;108(3):445\u201354. https:\/\/doi.org\/10.1016\/j.kint.2025.05.006.","journal-title":"Kidney Int"},{"issue":"6","key":"5260_CR49","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315. https:\/\/doi.org\/10.1016\/j.kint.2024.03.012.","journal-title":"Kidney Int"},{"issue":"6","key":"5260_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2025;392(6):531\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2410316.","journal-title":"N Engl J Med"},{"issue":"4","key":"5260_CR51","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.0000000534","volume":"36","author":"R Lafayette","year":"2025","unstructured":"Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, P\u00e9rez Valdivia M\u00c1, Wu MS, et al. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. J Am Soc Nephrol. 2025;36(4):645\u201356. https:\/\/doi.org\/10.1681\/ASN.0000000534.","journal-title":"J Am Soc Nephrol"},{"issue":"10417","key":"5260_CR52","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4.","journal-title":"Lancet"},{"issue":"6","key":"5260_CR53","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025;392(6):544\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2409415.","journal-title":"N Engl J Med"},{"issue":"15","key":"5260_CR54","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"5260_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05260-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:03:32Z","timestamp":1788361412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05260-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5260"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05260-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"517"}}